Allogene Therapeutics, Inc., a clinical-stage biotechnology company, has announced the publication of two significant abstracts ahead of the 2025 ASCO Annual Meeting. The first abstract highlights an oral presentation on ALLO-316, an investigational AlloCAR T product targeting CD70, which is being studied in patients with advanced or metastatic renal cell carcinoma. The presentation will discuss updated data from the Phase 1 TRAVERSE study, focusing on the Phase 1b expansion cohort where patients received a regimen of cyclophosphamide and fludarabine followed by a dose of 80 million CAR T cells. Additionally, the company will present a Trial-in-Progress poster on the Phase 2 ALPHA3 trial, which explores cemacabtagene ansegedleucel (cema-cel) as a first-line consolidation strategy for patients with large B-cell lymphoma who remain minimal residual disease positive after initial chemoimmunotherapy. These findings underscore Allogene's pioneering efforts in developing allogeneic CAR T products for cancer treatment.